InvestorsHub Logo
Followers 58
Posts 10034
Boards Moderated 1
Alias Born 09/21/2016

Re: kevli33 post# 167348

Monday, 10/01/2018 8:36:17 PM

Monday, October 01, 2018 8:36:17 PM

Post# of 458253

kevli33-thank you again. HH makes the point early on that what we are calling Precision Medicine as a method of research is long-long overdue. Those of us who have questioned why FDA and the Amyloid Thesis continued for as long as it did w/o a chance of ever producing anything other than a possible random (lightning bolt single case). AD complexity is being better understood at least as to scale, not all possible paths but it is a beginning down a path which will get us closer to effective treatments. Also note, the massive, expensive trials of the past are not the PM way of the future.

He provides convincing details on what must be done-proven, the time it will take and costs he expects. He clearly mentions Anavex and A2-73 trials in a positive manner. We are clearly in the lead as far as PM in AD is concerned as a process trials thinking.

Curious if any of the people at BIIB would have seen this presentation b/c if they did they would have serious concerns about the Amyloid Thesis (symptoms path) they claim to be on. Looks like a massive mistake in terms of money and more importantly, time. Time spent going down a path that (it would appear) goes no where. If I owned BIIB stock and I saw/understood what HH was saying here I would not be able to sleep.

If CTAD has BIIB doing presentation before HH and his PM description of A2-73 trial results then they are going to have a long day. He is clearly an/THE authority. Nice.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News